VEXAS Syndrome
Symptoms, Doctors, Treatments, Advances & More

VEXAS Syndrome Overview

Save information for later
Sign Up

Learn About VEXAS Syndrome

What is the definition of VEXAS Syndrome?
VEXAS syndrome is a severe inflammatory syndrome caused by a genetic mutation in bone marrow.
What are the symptoms of VEXAS Syndrome?
Symptoms of VEXAS syndrome usually occur between 45 and 80 years of age and may include recurrent fevers, inflammation of the blood vessels, fluid and infections in the lungs, skin and eye inflammation, deep vein clots, joint pain, infections of the cartilage of the ear and nose, anemia, and sensorineural hearing loss.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for VEXAS Syndrome?
There is currently no standard treatment for VEXAS syndrome. However, glucocorticoids have provided some symptom relief. Researchers are currently investigating bone marrow transplants and gene editing as possible treatments for VEXAS syndrome.
Who are the top VEXAS Syndrome Local Doctors?
Elite in VEXAS Syndrome
Elite in VEXAS Syndrome
Referral may be required
Before you request

Mayo Clinic-Rochester

200 1st St SW, 
Rochester, MN 
507-284-4474
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Koster is a Rheumatologist practicing medicine in Rochester, Minnesota. Dr. Koster is rated as an Elite provider by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Temporal Arteritis, Giant Cell Arteritis (GCA), VEXAS Syndrome, Tissue Biopsy, and Endoscopy. Dr. Koster is currently accepting new patients.

Elite in VEXAS Syndrome
Dr. David B. Beck
Medical Genetics | Rheumatology
Elite in VEXAS Syndrome
Dr. David B. Beck
Medical Genetics | Rheumatology
Referral may be required
Before you request

New York University

333 E 38th St, 
New York, NY 
646-356-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Beck is a Medical Genetics specialist and a Rheumatologist practicing medicine in New York, New York. Dr. Beck is rated as an Elite provider by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses VEXAS Syndrome, Relapsing Polychondritis, Hypotonia, and Polyarteritis Nodosa. Dr. Beck is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in VEXAS Syndrome
Elite in VEXAS Syndrome
Referral may be required
Before you request

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Warrington is a Rheumatologist practicing medicine in Virginia Beach, Virginia. Dr. Warrington is rated as an Elite provider by MediFind in the treatment of VEXAS Syndrome. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, Takayasu Arteritis, and Tissue Biopsy. Dr. Warrington is currently accepting new patients.

View All Doctors
What are the latest VEXAS Syndrome Clinical Trials?
A Single-arm Phase II With safety-run-in Multicenter Study of Momelotinib in Patients With VEXAS Syndrome With or Without Associated Myelodysplastic Syndrome
A Single-arm Phase II With safety-run-in Multicenter Study of Momelotinib in Patients With VEXAS Syndrome With or Without Associated Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: August 10, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: Multicenter, phase II trial with safety run-in to evaluate the efficacy and safety of momelotinib in patients with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome with or without associated myelodysplastic syndrome (MDS). The study will consist of two consecutive steps, a dose-finding safety run-in and a single-arm prospective phase II. During safety run-in phase, thre...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: VEXAS (vacuoles, E1 ubiqutin-activating enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described disorder with severe hematologic and rheumatologic manifestations caused by somatic variants in the ubiquitin- activating enzyme gene, UBA1, that is acquired in hematopoietic progenitor cells. Patients are often debilitated by autoinflammatory symptoms and there is currently no sta...

View All Clinical Trials